 |
|
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Jihyun An, Joo Hyun Sohn
Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online 2022 Dec 20 DOI: https://doi.org/10.3350/cmh.2022.0437
|
|
Citations to this article as recorded by
 Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis
Ryota Murata, Hiroshi Watanabe, Ryotaro Iwakiri, Mayuko Chikamatsu, Takao Satoh, Isamu Noguchi, Kengo Yasuda, Ayano Nishinoiri, Takuma Yoshitake, Hiroto Nosaki, Hitoshi Maeda, Toru Maruyama
Heliyon.2024; 10(3): e25485. CrossRef Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
Zijie Jin, Yan Yuan, Chen Zheng, Shijian Liu, Hongbo Weng
Journal of Diabetes and its Complications.2023; 37(8): 108558. CrossRef A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey
Stan Driessen, Vivian D. de Jong, Koen C. van Son, Tatiana Klompenhouwer, Yann Colardelle, Marco Alings, Cristophe Moreno, Stefan D. Anker, Manuel Castro Cabezas, Adriaan G. Holleboom, Diederick E. Grobbee, Maarten E. Tushuizen
United European Gastroenterology Journal.2023; 11(7): 654. CrossRef Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma
Rong Liu, Ming-Ping Qian, Ying-Yu Cui
Metabolism.2023; 147: 155665. CrossRef Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes
Amedeo Lonardo
Exploration of Drug Science.2023; : 239. CrossRef Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Chin-Hsiao Tseng
Cancers.2023; 15(17): 4276. CrossRef Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień
Medicina.2023; 59(10): 1789. CrossRef Extracellular Superoxide Dismutase Attenuates Hepatic Oxidative Stress in Nonalcoholic Fatty Liver Disease through the Adenosine Monophosphate-Activated Protein Kinase Activation
Heechul Nam, Ji Lim, Tae Kim, Eun Kim, Sae-Jong Oum, Si Bae, Cheol Park
Antioxidants.2023; 12(12): 2040. CrossRef Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Young Chang, Soung Won Jeong, Jae Young Jang
Clinical and Molecular Hepatology.2023; 30(1): 129. CrossRef
|